The South African launch of Prevenar®, a new polyvalent conjugate vaccine, has resulted in many questions being posed by health care providers and parents alike. Without a government policy on the role of this vaccine and considering its high cost, there is much debate on its place in therapy, cost benefit and long term epidemiological effect. This article provides an overview of the vaccine, its known advantages, potential disadvantages, place in therapy and administration.